Denali launches with ex-Genentech management and $217m-deep pockets
This article was originally published in Scrip
Three ex-Genentech executives have secured whopping $217m to launch new company Denali Therapeutics focused on developing therapies for neurodegenerative diseases.
You may also be interested in...
The amount of venture capital that Denali Therapeutics Inc. has raised and the number of collaborations it's negotiated in less than two years is pretty staggering for a startup biopharmaceutical company, not to mention a startup focused on the central nervous system and neurodegeneration.
A report released May 19 from the industry organization confirms that oncology is attracting the most funding, while some other surprising therapeutics areas have become of interest to investors.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.